Services
News
Research
Education Materials
Protocols
.

Mount Sinai Hospital is a University of Toronto patient care, teaching, and research centre.
Mount Sinai Hospital is a University of Toronto patient care, teaching, and research centre.

Pilot study of immunogenicity & reactogenicity of high versus standard dose influenza vaccine: An RCT

Study Purpose

To compare the antibody response to and risk of adverse events associated with high dose and standard dose influenza vaccine in younger adults

Who is being asked to participate?

People 18-64 years old who

  • have not yet been vaccinated against influenza this fall
  • have not received another vaccine or started new medications in the past 30 days
  • do not take immune suppressing therapy (chemo, radiation, systemic corticosteroids) or have an immunodeficiency condition

What is required?

  • be randomly assigned to receive either standard dose or high dose influenza vaccine (50:50 chance)
  • have two (2) blood samples taken: one before vaccination and one 21 days later to check for your antibody response
  • complete four (4) questionnaires: one before your vaccine, one 24 hours after vaccination, one 8 days after vaccination, and one next April

Who do I contact about participating?

Investigators

Dr. Allison McGeer, Dr. Brenda Coleman, Dr. Kevin Katz, Dr. Andrew Simor, Dr. Matthew Muller, Dr. Jeff Powis, and Dr. Janet McElhaney

MSH REB approval #14-0221-A

This website has been made possible through an unrestricted educational grant from Pfizer Canada Inc.
Copyright 1999-2007 Department of Microbiology, Mount Sinai Hospital, Toronto, Canada. All rights reserved.